Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody Persistence and Long Term Safety of VLA1553 in Adults
NCT04838444Phase 3Active, not recruiting
- Sponsor
- Valneva
- Start
- Apr 2021
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of chikungunya vaccine (live) in chikungunya virus infection, sponsored by Valneva. Started Apr 2021; status: active, not recruiting.
02
Drugs
chikungunya vaccine (live)
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT04838444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04838444.